Viatris is a global pharmaceutical company formed from the combination of Mylan and Pfizer’s Upjohn business. It focuses on generic and complex generic medicines, biosimilars and established brands across a very broad therapeutic footprint. Its customers include patients, pharmacies, wholesalers and health systems that rely on large-scale supply of more affordable, off-patent therapies.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 3,254.3 | — | -3,042 | — |
| Q2 2025 | 3,582.1 | — | -4.6 | — |
| Q3 2025 | 3,759.9 | — | -128.2 | — |
| Q4 2025 | 3,703.6 | — | -340.1 | — |
| Q1 2026 | 3,517 | 8.1% | 176.4 | — |
| Q2 2026 | 3,756.8 | 4.9% | -118.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Guardant Health, Inc. (GH), Entegris, Inc. (ENTG), Insmed Incorporated (INSM), PTC Inc. (PTC), Formula One Group (FWONA), Super Micro Computer, Inc. (SMCI)